Dyne Therapeutics, Inc.
DYN
$12.70
$0.746.19%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 15.93M | 15.30M | 12.86M | 9.70M | 24.62M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 122.37M | 97.11M | 105.66M | 71.96M | 69.16M |
Operating Income | -122.37M | -97.11M | -105.66M | -71.96M | -69.16M |
Income Before Tax | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M |
EBIT | -122.37M | -97.11M | -105.66M | -71.96M | -69.16M |
EBITDA | -121.87M | -96.66M | -105.22M | -71.56M | -68.77M |
EPS Basic | -1.05 | -0.88 | -0.96 | -0.70 | -0.81 |
Normalized Basic EPS | -0.66 | -0.55 | -0.60 | -0.44 | -0.51 |
EPS Diluted | -1.05 | -0.88 | -0.96 | -0.70 | -0.81 |
Normalized Diluted EPS | -0.66 | -0.55 | -0.60 | -0.44 | -0.51 |
Average Basic Shares Outstanding | 109.91M | 101.98M | 100.88M | 92.51M | 81.04M |
Average Diluted Shares Outstanding | 109.91M | 101.98M | 100.88M | 92.51M | 81.04M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |